LIAISON PLEX® Gram-Negative Blood Culture Assay
Optimize Treatment in Hours—Not Days
The LIASON PLEX® Gram-Negative Blood Culture Assay integrates with your standard-of-care workflow for maximum clinical impact through the molecular detection and differentiation of 27 targets including 19 gram-negative bacteria frequently found to cause bacteremia, plus 8 resistance genes associated with these bacteria.
Powered by Bioz
Disease state
Approximately 250,000 US patients are diagnosed with bloodstream infections (BSIs) annually. Sepsis caused by a BSI has an average mortality rate of 16-40% and delay in appropriate treatment can add additional risk for the patient. Sepsis also has the unfortunate distinction of being the most expensive cause of hospitalization in the US at more than $20 billion per year.1
Gram-negative bacteremia accounts for approximately 30% of all positive blood cultures. Invasive gram-negative bacteremia often requires therapeutic adjustments from more generalized empiric therapy.
1. National Institutes of Health (NIH), 2018
Sepsis is a disease associated with high mortality.
The value of LIAISON PLEX® Gram-Negative Blood Culture Assay
Empower clinicians to rapidly optimize treatment for gram-negative bacteremia.
Clinical impact
Identification of bacteria and resistance genes that allow for rapid treatment optimization.
Outstanding economic value
Panel selection based on Gram stain helps improve diagnostic stewardship and control operational costs.
The right assay design
Non-amplified molecular chemistry helps minimize false results that may occur with PCR-based amplification of non-viable DNA in blood culture media.
How the LIAISON PLEX® Gram-Negative Blood Culture Assay works
LIAISON PLEX® Gram-Negative Blood Culture Assay is a syndromic in vitro diagnostic test for the detection and identification of invasive pathogenic gram-negative bacteria from positive culture samples. Subculturing is necessary for the identification and susceptibility testing of organisms not detected by the assay, in conjunction with standard of care culture workflows.
Transfer sample
Transfer sample to cartridge.
Scan
Scan the Sample ID and the Cartridge ID.
Load and run
Load the cartridge, initiate the Run, and walk away.
LIAISON PLEX® Gram-Negative Blood Culture (BCN) Assay
Gram-Negative Bacteria |
|
Resistance Genes |
|---|---|---|
| Acinetobacter baumannii |
Klebsiella variicola |
CTX-M (blaCTX-M) |
| Acinetobacter spp. |
Morganella morganii |
IMP (blaIMP) |
| Citrobacter spp. |
Neisseria meningitidis |
KPC (blaKPC) |
| Escherichia coli |
Proteus spp. |
NDM (blaNDM) |
| Enterobacter spp. |
Pseudomonas aeruginosa |
OXA (blaOXA) |
| Enterobacteriaceae/Morganellaceae |
Pseudomonas spp. |
SME (blaSME) |
| Haemophilus influenzae |
Salmonella spp. |
VIM (blaVIM) |
| Klebsiella oxytoca |
Serratia marcescens |
MCR |
| Klebsiella pneumoniae |
Stenotrophomonas maltophilia |
To be used on the LIAISON PLEX® System
The LIAISON PLEX® System is a next-generation, multiplex, sample-to-answer molecular diagnostic platform. Its proprietary Flex® Software enables users to pay only for required targets, with the option to customize results as needed.
LIAISON PLEX®
Flexibility like never before with an easy-to-use, automated system for customizable syndromic testing.
LIAISON PLEX® Gram-Negative Blood Culture Assay ordering info
Part Name |
Kit Size |
Registration Status |
Part Number |
|---|---|---|---|
|
LIAISON PLEX® Gram-Negative |
12 |
IVD |
20-005-303 |